Cart
sales@molnova.com
Conatumumab
CAS No. 896731-82-1
Conatumumab( —— )
Catalog No. M36720 CAS No. 896731-82-1
Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 575 | Get Quote |
|
| 5MG | 907 | Get Quote |
|
| 10MG | 1454 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameConatumumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionConatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5.
-
DescriptionConatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2)(Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
-
In VitroCell Viability Assay Cell Line:Colo205, H-2122, and MiaPaCa2 cells Concentration:0-10 μg/mL Incubation Time:24 h Result:Dose-dependently inhibited cell viability.
-
In VivoAnimal Model:Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors Dosage:0, 0.1, 0.3, 1, 3, 10, 30, 100 μg Administration:Intraperitoneal injection (i.p.), twice weekly.Result:Dose-dependently inhibited tumor growth.Induced caspase-3 activation in tumors (determined by IHC).
-
Synonyms——
-
PathwayApoptosis
-
TargetTNF
-
RecptorTNF
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number896731-82-1
-
Formula Weight145.65 (kDa)
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. ?
molnova catalog
related products
-
MOSLOFLAVONE
MOSLOFLAVONE showed promising anti-inflammatory activity via inhibition of TNF-α and IL-1β with IC50 values of 0.71 μM and ?7.8 μM respectively.
-
Lenalidomide
Lenalidomide (initially known as CC-5013 and marketed as Revlimid? by Celgene) is a derivative of thalidomide introduced in 2004.
-
Hernandezine
Hernandezine is an activator of AMPK activator and a selective reversing agent for ABCB1-mediated MDR in cancer cells.
